Medline (MDLN) Faces FDA Probe, Stock Falls Amid Quality Concerns
Medline Inc. (NASDAQ: MDLN) is under investigation by Kessler Topaz Meltzer & Check, LLP for potential securities law violations, following an FDA warning letter detailing significant manufacturing quality issues. The company's stock saw a notable decline after the news, with shares dropping over 7% and later another 12% following Q2 results.
Investors who purchased Medline Inc. (NASDAQ: MDLN) Class A common stock and experienced losses may have legal recourse and are encouraged to contact Kessler Topaz Meltzer & Check, LLP for further information regarding their rights.